Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in antibodies and recombinant proteins, has successfully raised nearly RMB 200 million (approximately USD 27.8 million) in a Series B+ financing round. The funding was led by China Medical System Holdings Ltd., with participation from Orient Jiafu Asset Management and other investors.
Funding to Enhance Personnel and Expand Production Capabilities
The proceeds from this financing round will be allocated towards enhancing the personnel team and expanding HealSun Biopharm’s commercial production line for antibodies, recombinant proteins, and antibody-drug conjugates (ADCs). This strategic investment aims to bolster the company’s operational capabilities and meet the growing demand in the biopharmaceutical sector.
Strategic Partnership with China Medical System Holdings
China Medical System Holdings, the leading investor in this round, has previously established a strategic partnership with HealSun Biopharm. This collaboration is expected to further strengthen HealSun’s position in the market and enhance its ability to deliver high-quality biopharmaceutical products.-Fineline Info & Tech
